Latest Information Update: 29 May 2001
At a glance
- Originator Mundipharma International
- Developer Shionogi
- Class Analgesics
- Mechanism of Action Opioid receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer pain
Most Recent Events
- 29 May 2001 Discontinued-III for Cancer pain in Japan (Unknown route)
- 26 Jun 2000 Suspended-III for Cancer pain in Japan (Unknown route)
- 14 Jan 1998 New profile